Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document

References

• Ferrandiz C, Bordas X, Garcia-Patos V, et al. Prevalence of psoriasis in Spain (epiderma project: phase I). J Eur Acad Dermatol Venereol. 2001;15(1):20–23.
   PubMed Web of Science ®Google Scholar
• Ferrandiz C, Carrascosa JM, Toro M. Prevalence of psoriasis in Spain in the age of biologics. Actas Dermosifiliogr. 2014;105(5):504–509.
   PubMedGoogle Scholar
• Ferrandiz Foraster C, Garcia-Diez A, Lizan Tudela L, et al. Impact of psoriasis on health-related quality of life. Med Clin. 2007;128(9):325–329.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258.
   PubMed Web of Science ®Google Scholar
• Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1:CD011535.
   PubMed Web of Science ®Google Scholar
• Sacristan JA, Dilla T, Diaz-Cerezo S, et al. Patient-physician discrepancy in the perception of immune-mediated inflammatory diseases: rheumatoid arthritis, psoriatic arthritis and psoriasis. A qualitative systematic review of the literature. PLoS One. 2020;15(6):e0234705.
   PubMed Web of Science ®Google Scholar
• Kitchen H, Cordingley L, Young H, et al. Patient-reported outcome measures in psoriasis: the good, the bad and the missing!. Br J Dermatol. 2015;172(5):1210–1221.
   PubMed Web of Science ®Google Scholar
• Nelson PA, Kane K, Pearce CJ, et al. ‘New to me’: changing patient understanding of psoriasis and identifying mechanisms of change. The Pso Well® patient materials mixed-methods feasibility study. Br J Dermatol. 2017;177(3):758–770.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Jo SJ, Naldi L, et al. A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey. Br J Dermatol. 2018;179(1):173–181.
   PubMed Web of Science ®Google Scholar
• Baker EL, Coleman CI, Reinhart KM, et al. Effect of biologic agents on non-PASI outcomes in moderate-to-severe plaque psoriasis: systematic review and meta-analyses. Dermatol Ther. 2012;2(1):9.
   PubMedGoogle Scholar
• Florek AG, Wang CJ, Armstrong AW. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. Arch Dermatol Res. 2018;310(4):271–319.
   PubMed Web of Science ®Google Scholar
• Gorelick J, Shrom D, Sikand K, et al. Understanding treatment preferences in patients with moderate to severe plaque psoriasis in the USA: results from a cross-sectional patient survey. Dermatol Ther. 2019;9(4):785–797.
   Web of Science ®Google Scholar
• Belinchon I, Rivera R, Blanch C, et al. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357–2367.
   PubMed Web of Science ®Google Scholar
• Nast A, Reytan N, Rosumeck S, et al. Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. J Eur Acad Dermatol Venereol. 2008;22(11):1337–1342.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.
   PubMed Web of Science ®Google Scholar
• Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology-National psoriasis foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019;81(3):775–804.
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.
   PubMed Web of Science ®Google Scholar
• Puig L, Carrascosa JM, Carretero G, et al. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment. Spanish psoriasis group of the Spanish academy of dermatology and venereology. Actas Dermosifiliogr. 2013;104(8):694–709.
   PubMedGoogle Scholar
• Sanchez-Regana M, Aldunce Soto MJ, Belinchon Romero I, et al. Evidence-based guidelines of the Spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles). Actas Dermosifiliogr. 2014;105(10):923–934.
   PubMedGoogle Scholar
• Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris-update 2015-short version-EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277–2294.
   PubMed Web of Science ®Google Scholar
• Nast A, Jacobs A, Rosumeck S, et al. Methods report: European S3-guidelines on the systemic treatment of psoriasis vulgaris-update 2015-EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):e1–e22.
   Web of Science ®Google Scholar
• Nast A, Spuls PI, van der Kraaij G, et al. European S3-guideline on the systemic treatment of psoriasis vulgaris - update apremilast and Secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2017;31(12):1951–1963.
   PubMed Web of Science ®Google Scholar
• Amatore F, Villani AP, Tauber M, et al. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464–483.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):774–790.
   PubMed Web of Science ®Google Scholar
• Dauden E, Puig L, Ferrandiz C, et al. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: psoriasis group of the Spanish academy of dermatology and venereology. J Eur Acad Dermatol Venereol. 2016;30(2):1–18.
   PubMed Web of Science ®Google Scholar
• Baker C, Mack A, Cooper A, et al. Treatment goals for moderate to severe psoriasis: an Australian consensus. Australas J Dermatol. 2013;54(2):148–154.
   PubMed Web of Science ®Google Scholar
• Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British association of dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177(3):628–636.
   PubMed Web of Science ®Google Scholar
• Seneschal J, Lacour JP, Bewley A, et al. A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL). J Eur Acad Dermatol Venereol. 2020;34(11):2566–2573.
   PubMed Web of Science ®Google Scholar
• Chalmers RJ. Assessing psoriasis severity and outcomes for clinical trials and routine clinical practice. Dermatol Clin. 2015;33(1):57–71.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Clark CM, Chalmers RJ, et al. A systematic review of treatments for severe psoriasis. Health Technol Assess. 2000;4(40):1–125.
   PubMedGoogle Scholar